TRIP4 (thyroid hormone receptor interactor 4) functions as a transcriptional coactivator that associates with nuclear receptors, transcriptional coactivators, and basal transcription factors to facilitate nuclear receptor-mediated transcription 12. The protein contains an N-terminal C2HC5-like zinc-finger domain and a conserved C-terminal ASCH domain that binds DNA in a sequence-independent manner through positively charged surface patches 3. TRIP4 plays critical roles in thyroid hormone receptor, estrogen receptor, and androgen receptor transactivation, as well as in NF-kappa-B, SRF, and AP1 signaling pathways 124. The protein is also part of the ribosome quality control (RQC) pathway, participating in the degradation of nascent peptide chains during problematic translation 56. Pathogenic variants in TRIP4 cause congenital muscular dystrophy and spinal muscular atrophy with bone fractures, characterized by neonatal hypotonia, respiratory distress, and joint contractures 7. In cancer contexts, TRIP4 promotes tumor progression and resistance to therapy, including sorafenib resistance in hepatocellular carcinoma through the MED8-TRIP4 axis 8 and cervical cancer progression via GATA2 transcriptional activation 910. These diverse functions highlight TRIP4's importance in transcriptional regulation, protein quality control, and disease pathogenesis.